BusinessPostCorner.com
No Result
View All Result
Tuesday, July 15, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

Pfizer shares tumble on weak forecast for 2024 revenues

December 13, 2023
in Finance
Reading Time: 2 mins read
A A
0
Pfizer shares tumble on weak forecast for 2024 revenues
ShareShareShareShareShare

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Pfizer shares tumbled more than 7 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid-19 products.

The company said on Wednesday it expected 2024 revenues to fall to between $58.5bn and $61.5bn. An average of analyst estimates compiled by Reuters had seen revenues of $63.17bn for the same period.

When it released third-quarter earnings in October, Pfizer said it expected 2023 revenues to fall to between $58bn and $61bn, down from a previously issued guidance, in May this year, of $67bn to $71bn.

The drugmaker on Wednesday said it also expected adjusted earnings per share to come in at between $2.05 and $2.25, below Reuters estimates of $3.16 per share.

After raking in billions of dollars through sales of the Covid vaccine it co-developed with Germany’s BioNTech during the pandemic and seeing share prices surge, Pfizer has struggled to reorientate its pipeline and to reassure investors about its growth potential.

“We are acutely aware that all these uncertainties are making it difficult to project the future revenues of Pfizer — and are also affecting our stock price,” Albert Bourla, the company’s chief executive, said on a recent earnings call.

The same concerns have plagued other drugmakers whose sales surged during the pandemic, such as Moderna and Pfizer’s partner BioNTech.

Recommended

In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn.

But an increase of $500mn in cost cutting announced on Wednesday was still not enough to please investors. New York-listed shares lost 7.3 per cent before the open, after losing more than 44 per cent this year.

To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday.

Credit: Source link

ShareTweetSendPinShare
Previous Post

a16z and Founders Fund lead $13.5 million round for crypto onboarding startup Dynamic Labs

Next Post

Elon Musk's Tesla recalls two million cars over Autopilot defect

Next Post
Elon Musk's Tesla recalls two million cars over Autopilot defect

Elon Musk's Tesla recalls two million cars over Autopilot defect

Asia is reeling but is anyone winning?

Asia is reeling but is anyone winning?

July 11, 2025
Africa’s top garment exporter could fold under US tariffs, minister says

Africa’s top garment exporter could fold under US tariffs, minister says

July 12, 2025
High-Leverage Crypto Trader James Wynn Deletes X Account After Nine-Digit Losses

High-Leverage Crypto Trader James Wynn Deletes X Account After Nine-Digit Losses

July 13, 2025
How will the new overtime and tip deduction affect employers?

How will the new overtime and tip deduction affect employers?

July 10, 2025
Donald Trump asked Volodymyr Zelenskyy if Ukraine could hit Moscow, say people briefed on call

Donald Trump asked Volodymyr Zelenskyy if Ukraine could hit Moscow, say people briefed on call

July 15, 2025
Apple’s AI efforts ‘have struck midnight’ and the only way it can stop getting further behind is acquiring Perplexity, analyst Dan Ives says

Apple’s AI efforts ‘have struck midnight’ and the only way it can stop getting further behind is acquiring Perplexity, analyst Dan Ives says

July 9, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

Deadly ICE raids on California cannabis farms yield over 360 arrests in one of largest anti-immigrant crackdowns by Trump

Deadly ICE raids on California cannabis farms yield over 360 arrests in one of largest anti-immigrant crackdowns by Trump

July 15, 2025
LA Sheriff’s Deputies Used Badges to Help Crypto ‘Godfather’ Extort Victims

LA Sheriff’s Deputies Used Badges to Help Crypto ‘Godfather’ Extort Victims

July 15, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!